10-Q: Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides Clinical Program Update

Astria Therapeutics reported a net loss of $19.9 million for the first quarter of 2024, while highlighting progress in its clinical programs for STAR-0215 and STAR-0310.

Summary

• Astria Therapeutics reported a net loss of $19.9 million for the first quarter of 2024, compared to a net loss of $11.2 million for the same period in 2023.
• Research and development expenses increased to $15.7 million, up from $8.0 million in the first quarter of 2023, primarily due to the advancement of the STAR-0215 and STAR-0310 programs.
• General and administrative expenses rose to $8.4 million, compared to $5.5 million in the prior year period.
• The company's cash, cash equivalents, and short-term investments totaled $369.9 million as of March 31, 2024.
• Astria estimates its current funds will support operations into mid-2027, including the completion of a Phase 3 trial for STAR-0215 and the advancement of STAR-0310 through a Phase 1a trial.
• The company completed a public offering in February 2024, raising net proceeds of $117.2 million.
• The company also completed sales under its 2021 ATM program, raising net proceeds of $20.0 million.
• The company has initiated a new ATM program for up to $150 million.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the clinical trial data for STAR-0215 is promising and the company has a strong cash position, the increased net loss and the need for future capital raises temper the overall outlook. The company is making progress but faces significant financial and development risks.

Positives

• The company has a strong cash position of $369.9 million, which is expected to fund operations into mid-2027.
• Initial data from the ALPHA-STAR trial of STAR-0215 showed significant reductions in HAE attack rates and rescue medication use.
• STAR-0215 was generally well-tolerated in the ALPHA-STAR trial with no serious treatment-emergent adverse events.
• The company is progressing STAR-0310 towards clinical trials with an anticipated IND submission by year-end 2024.
• The company successfully raised $117.2 million through a public offering in February 2024.
• The company completed sales under its 2021 ATM program, raising net proceeds of $20.0 million.

Negatives

• The company reported a net loss of $19.9 million for the first quarter of 2024, an increase from the $11.2 million loss in the same period of 2023.
• Research and development expenses increased significantly to $15.7 million, reflecting the high cost of clinical development.
• The company has an accumulated deficit of $600.5 million.
• The company has not generated any product revenues and is reliant on external funding.

Risks

• The company is dependent on the success of its product candidates, particularly STAR-0215 and STAR-0310, which are still in development.
• The company will need to raise substantial additional funding to complete the development and commercialization of its product candidates.
• Clinical trials are subject to risks and uncertainties, and results may not be positive or lead to regulatory approvals.
• The company faces competition from other companies developing treatments for HAE and AD.
• The company's operating plan may change, requiring additional financing sooner than planned.
• The company has incurred operating losses and negative cash flows since its inception.

Future Outlook

The company expects its current cash, cash equivalents, and short-term investments to fund operations into mid-2027, including the completion of a Phase 3 trial for STAR-0215 and the advancement of STAR-0310 through a Phase 1a trial. The company plans to start a pivotal Phase 3 trial for STAR-0215 in the first quarter of 2025 and submit an IND for STAR-0310 by year-end 2024.

Management Comments

• The company is focused on developing first-choice therapies that improve the health and outcomes of patients with allergic and immunological diseases.
• The goal for STAR-0215 is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE.
• The vision for STAR-0215 is to become the first-choice preventative treatment for HAE with administration every three and six months.
• The goal for STAR-0310 is to reduce disease activity, relapse rate, and treatment burden for patients with moderate-to-severe AD.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on treatments for rare and immunological diseases. The HAE market is growing, and there is a need for more patient-friendly treatment options. The AD market also has significant unmet needs, with current treatments often insufficient or having undesirable side effects. The company is positioning its product candidates to address these needs with differentiated profiles.

Comparison to Industry Standards

• The reported 92-96% reduction in monthly attack rate for STAR-0215 in the ALPHA-STAR trial is highly competitive compared to existing HAE treatments such as Takhzyro (lanadelumab) and Haegarda (C1 esterase inhibitor), which also aim to reduce attack frequency.
• The goal of achieving 3-6 month dosing for STAR-0215 is a significant advantage over current treatments that require more frequent administration, potentially improving patient compliance and quality of life.
• The development of STAR-0310 as a long-acting OX40 inhibitor for AD is in line with the industry trend of exploring novel mechanisms of action to address the limitations of current treatments like topical corticosteroids and biologics such as Dupixent (dupilumab).
• Companies like Regeneron (Dupixent) and Incyte (Opzelura) are key competitors in the AD space, and Astria's success will depend on demonstrating a superior safety and efficacy profile for STAR-0310.
• The company's cash runway into mid-2027 is relatively strong compared to many other clinical-stage biotech companies, providing a solid foundation for continued development.

Stakeholder Impact

• Shareholders may be impacted by the company's financial performance and the need for additional capital raises.
• Employees are impacted by the company's growth and development plans.
• Patients with HAE and AD may benefit from the development of new treatment options.
• The company's suppliers and partners are impacted by the company's research and development activities.

Next Steps

• The company plans to report additional data from the ALPHA-STAR trial in the second half of 2024.
• The company plans to start a pivotal Phase 3 trial for STAR-0215 in the first quarter of 2025.
• The company anticipates submitting an IND for STAR-0310 by year-end 2024.
• The company plans to initiate a Phase 1a clinical trial of STAR-0310 in the first quarter of 2025.
• The company expects to report initial safety and efficacy data from ALPHA-SOLAR in mid-2025.

Key Dates

Keywords

Hereditary Angioedema, Atopic Dermatitis, STAR-0215, STAR-0310, Clinical Trials, Monoclonal Antibody, Phase 3, Phase 1, Biopharmaceutical, Research and Development, Financial Results, OX40, Plasma Kallikrein